Dear Friends,

It’s been over 30 years since our friend, founder and inspiration, Sharon Monsky, challenged us to achieve one overarching goal: find a cure for scleroderma and then close the doors. We remain as dedicated today as ever despite a variety of challenges — including the pandemic that shut down the country and most of the research labs that we fund. However, for the period of this report (through the end of 2019), we have continued to make exciting progress for our patients.

As we have changed our fiscal year, this report will cover two periods: FY 2019 ending April 30, 2019 and a stub year for the remainder of 2019. Henceforth, we will report on a calendar year basis.

This 2018-19 period has been an especially significant one for us. As you know, the Scleroderma Research Foundation is the leader in nonprofit funding of scleroderma-oriented research. Over the 19 months ending December 2019, the SRF has been able to leverage its reputation for research leadership and its established role in bringing world-class talent to the problem of scleroderma. Those efforts have made a significant impact on translational and clinical issues that directly affect the patient community. Among the key accomplishments:

• **Novel drugs for our patients:** We were granted a major speaking slot as a patient advocate at the July 2019 ACR AdCom meeting in Bethesda, MD, which was convened to consider whether to recommend approval of the first drug for scleroderma fibrotic lung disease. And we are delighted to report that in September 2019, this drug (Boehringer Ingelheim's Ofev) was approved and is now a part of the arsenal that physicians have for this challenging complication of scleroderma.

• **GRASP:** The SRF hosted a meeting of the GRASP (Genome Research in African American Scleroderma Patients) consortium at the NIH in May 2019, punctuating a productive period for the consortium which included additional publications.

• **New disease measures:** We partnered with the Scleroderma Clinical Trials Consortium to deploy the Betty Benedict legacy gift towards the development of an essential resource that is still missing in the community: an accurate measure of disease activity that is sensitive to small changes.

• **Research community leadership:** We hosted our annual SRF Science Workshop in April 2019, bringing together all SRF funded researchers, advisors and selected guests. We continued our sponsorship of the International Scleroderma Workshop — a biannual meeting of scleroderma researchers from around the world, which took place in August 2019 in Cambridge, UK.

• **ACR leadership:** In November 2019, at the American College of Rheumatology meeting, attended by 30,000 rheumatologists from around the world, the SRF held major meetings to update the GRASP consortium, a Friends and Family networking dinner with Dr. Antony Rosen as speaker, and hosted a Conquer industry session as well as a Conquer Annual Meeting.

• **At year end,** we were delighted to report two fantastic additions to the Scientific Advisory Board — Dr. Dan Littman and Dr. Lloyd Krickstein. Their bios are presented in the body of this report and they are already diligently engaged in supporting our efforts.

Our mission and focus have not changed, but our presence and reputation as a leader in the field has allowed us to broaden our scope of influence and to expand the types of research we support. A noteworthy achievement this year has been the advancement within CONQUER — a first-of-its-kind nationwide longitudinal registry that was founded and is run by the SRF. By the end of 2019, we enrolled over 300 unique patients and collected over 450 blood samples. As previously noted, this effort will yield the gold-standard database to track and understand the trajectory of scleroderma in the modern context. Clinicians and scientists and our pharmaceutical partners will use the underlying data in a variety of ways: To determine which disease features are associated with or predict outcomes; identify patients requiring early/aggressive intervention — as well as those to watch — and, among other goals, drive more personalized and effective therapy for patients. As a critical, pre-competitive resource, we are delighted to report that we have been able to partner with two companies on Conquer, and we are in advanced conversations about additional support. Thank you, Boehringer Ingelheim and Actelion for your leadership.

We also recognize that serious business sometimes requires serious fun. And since our beginning, *Cool Comedy • Hot Cuisine* has brought together friends along with world-class performers for a night of great food and laughter in support of scleroderma research. On behalf of all of us at the SRF, I offer my thanks to fellow Board Members Susan Feniger and Bob Saget for being our shining stars once again. This effort just keeps on giving. In the past period, we have held three events, two in NY and one in LA. Overall, these events raised over $2.5 million for scleroderma research!

The creativity and commitment of our volunteers, including the indomitable grassroots Cure Crew, are pillars of the SRF. It’s because of your contributions that we have arrived where we are today, and are able to continue to move forward, onward, and upward.

Thank you! And our efforts to connect and communicate with our community via social media continue to evolve. We look forward to reaching out to you more frequently through multiple platforms and keeping you apprised, amused and inspired on a real-time basis.

The SRF maintains a lean team. In addition to our board of directors, scientific advisory board, and funded investigators, our San Francisco office is comprised of five tireless employees who are committed to our efforts. On behalf of Scleroderma Research Foundation, thank you for all your support.

It’s because of your contributions that we have arrived where we are today, and are able to continue to move forward, onward, and upward.

Sincerely,

Luke Evnin, PhD
Chairman

---

**SRF Leadership**

**SRF Board of Directors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Delany*</td>
<td>Founder</td>
</tr>
<tr>
<td>Sharon Dobie, MD</td>
<td>Secretary</td>
</tr>
<tr>
<td>Susan Feniger</td>
<td>Treasurer</td>
</tr>
<tr>
<td>Eric Kau, MD</td>
<td></td>
</tr>
<tr>
<td>David Knoller</td>
<td></td>
</tr>
<tr>
<td>Violetta Merin</td>
<td></td>
</tr>
<tr>
<td>Bob Saget</td>
<td></td>
</tr>
<tr>
<td>Caryn Zucker</td>
<td></td>
</tr>
</tbody>
</table>

*Emeritus*
MISSION & VISION

Our Mission
The mission of the Scleroderma Research Foundation is to fund and facilitate the most promising, highest quality research aimed at improved treatment options and, ultimately, a cure for scleroderma.

What We Do
Founded in 1987, The Scleroderma Research Foundation (SRF) is America’s leading nonprofit investor in scleroderma research. Research is at the center of all we do, and we are singularly focused on bringing the best minds to work toward a cure for scleroderma. The SRF research program devotes most of its research budget to long-term fundamental discoveries in basic, translational and clinical projects. We seek to deepen knowledge and understanding of this life-threatening condition by facilitating collaboration among the world’s top scientists and clinicians to open new doors to therapeutic development and ultimately, a cure.

About Scleroderma
One of the most serious and complex of all rheumatic disorders, scleroderma is not a single disease, but a set of related disorders involving a similar set of symptoms, making a concise definition – and diagnosis – very difficult. The disease often causes the hardening and tightening of the skin and connective tissues, but depending on the subtype of illness, scleroderma also can severely damage the body’s digestive, respiratory and circulatory systems. It can be disfiguring, debilitating and even deadly. Systemic sclerosis affects approximately 100,000 people in the U.S. and strikes men, women and children of all ages and ethnicities. However, 80% of those afflicted with the disease are women in the prime of their lives, 30-50 years old.

The cause of scleroderma is unknown, yet significant progress has been made in managing the symptoms and some of the most serious complications of scleroderma. People with the disease are living longer, fuller lives. Still, no therapies yet exist to halt or reverse the disease process.

Our Guiding Principles

We believe in collaboration.
We unite exceptional scientists and clinicians across many disciplines, in order to advance our understanding of scleroderma.

We promote discovery.
We invest $2.0M+ annually to fund pioneering research studies led by the most gifted scientists, because research is the key.

We advocate for comprehensive care.
The SRF helps to sustain Scleroderma Centers of Excellence so patients can receive the most comprehensive care.

Our Vision: A World Without Scleroderma
SRF Founder Sharon Monsky envisioned a future where those living with scleroderma would have access to new treatments, and ultimately, a cure. She proudly stated that the SRF was “in business to go out of business.” Today, over 30 years later, we are accelerating our understanding of scleroderma through our innovative research program. Our focus on medical research enables gifted researchers and clinicians to explore promising ideas, share encouraging findings, and take us closer to our goal every day.
Scientific Advisory Board

The individuals on the SRF’s Scientific Advisory Board (SAB) are some of the world’s most honored and distinguished scientists, and give their time and insights freely to the SRF’s research endeavors. These renowned researchers guide the Foundation’s research program, evaluate research proposals, and make funding recommendations.

Each year, the SAB convenes and leads the annual SRF Science Workshop, which brings together thought leaders from diverse backgrounds, to exchange information and ideas. The results of this intensive work are new alliances and ideas that further develop the road map for vital research, which will lead to better treatments and ultimately to a cure for scleroderma.

Bruce Alberts, Ph.D
Chairman of the SRF Scientific Advisory Board
UCSF
A renowned biochemist and distinguished professor at UCSF, Dr. Alberts has also been recognized for his leadership in science policy and education. He served two terms as the President of the National Academy of Sciences, three years as a U.S. Science Envoy, and he has received countless awards, including the National Medal of Science from President Barack Obama. Dr. Alberts is a member of the National Academy of Sciences.

Dan Littman, MD, Ph.D
New York University
Howard Hughes Medical Institute
Dr. Littman, a world-renowned immunologist, heads a large research group at NYU that focuses on T cells, a critical cell of the adaptive immune system and its role in inflammatory diseases. Dr. Littman also has extensive biopharmaceutical experience, currently serving on the Board of Directors of Pfizer and having founded two biotech companies: Vedanta Biosciences, Inc. and Orao Pharmaceuticals, Ltd.. Dr. Littman has been an Investigator of the Howard Hughes Medical Institute since 1987 and is a member of the National Academy of Sciences and the Institute of Medicine.

Lloyd Klickstein, MD, Ph.D
Chief Innovation Officer
Adicet Bio, Inc.
Dr. Klickstein, a rheumatologist and immunologist, has had a long and successful career in the biopharmaceutical industry and biomedical research. Prior to joining Adicet Bio, Inc., he served for thirteen years at Novartis as the Head of NIDU — the unit that researches new drug targets and evaluates them for potential drug development. Prior to his industrial career, he was a physician-scientist over more than a decade with his own successful lab at Harvard’s BWH where he also had a clinical practice. Dr. Klickstein also serves as an independent board member at Blade Therapeutics.

David Botstein, Ph.D
Chief Scientific Officer
Calico Life Sciences
An eminent geneticist whose research laid the foundation for the Human Genome Project, Dr. Botstein has been at the forefront of genomic research for decades. Having been a distinguished professor at MIT, Princeton and Stanford, he now leads the effort to understand the aging process at Calico, a Google company. A recipient of the Breakthrough Prize and numerous other prestigious awards, Dr. Botstein is a member of the National Academy of Sciences and the Institute of Medicine.

Antony Rosen, MD
Vice Dean for Research
Johns Hopkins University
A Distinguished Professor at Johns Hopkins University and a rheumatologist, Dr. Rosen’s research focuses on autoimmunity in the rheumatic diseases. By studying subgroups of patients with distinct phenotypes, disease trajectories and specific autoimmune responses, his research group is at the forefront of identifying the molecular mechanisms that are disrupted in scleroderma. Dr. Rosen is also the Chair of the Department of Rheumatology and Co-Director of the Johns Hopkins Precision Medicine Initiative.

Dan Kastner, MD, Ph.D
Scientific Director
Intramural Program of the National Human Genome Research Institute (NHGRI)
Dr. Kastner’s distinguished career at the NIH has been focused on using genetic and genomic strategies to understand inherited disorders of inflammation. Prior to joining the NHGRI, Dr. Kastner, a rheumatologist, also served for many years as the Clinical Director of the Intramural Program of the National Institute of Arthritis and Musculoskeletal Diseases (NIAMS). He has received numerous awards, including the NIH Director’s Award, and the Service to America Award (“Sammie”) as the Federal Employee of the Year. Dr. Kastner is a member of the National Academy of Sciences and the Institute of Medicine.

Bruce Wintroub, MD
Chair of Dermatology
UCSF
Dr. Wintroub is a Professor and Chair of the Department of Dermatology and Vice Dean of Medicine at UCSF. His research has focused on the interface of dermatology and immunology in several diseases that affect the skin, including scleroderma. Dr. Wintroub has also served as the Chairman of the Dermatology Foundation.
Each year, the SRF receives and evaluates applications for research projects aimed at understanding the biological processes that go awry in scleroderma and how these might be addressed therapeutically. The process for determining which projects get funded is holistic. We ask numerous questions in considering projects for funding, such as: does this project answer a fundamental question about the scleroderma disease process? Would this project yield unique insights into targeting therapies to patients?

We also consider the investigator’s potential contributions to the SRF research program with questions such as: would this project and investigator contribute unique and relevant cross-disciplinary insights to our understanding of scleroderma? Does the investigator have the appropriate skills, background and access to excellent mentorship, if needed, to accomplish the project goals? Will this investigator make a real effort to add to our community through collaboration and generous sharing of ideas or resources?

All applicants, whether new or seeking continued funding, present their projects to the SRF’s Scientific Advisory Board and other attendees at the SRF Annual Workshop. There, assumptions are challenged, the project’s relevance and limitations are probed, and constructive critique and collaborative discussion ensues.

It is worth noting that, at the end of the process, there are always worthy projects that the SRF cannot fund, due to budgetary considerations. Our goal, and deepest hope, is to continue to expand the SRF’s ability to fund great research in our search for a cure.

In the following pages, please read about a few selected research projects.
Epigenetics of Sex Differences in Scleroderma

Howard Chang, MD, PhD
Stanford University of Medicine, Howard Hughes Medical Institute

PROJECT OVERVIEW

One of Dr. Chang’s SRF-funded projects aims to discover why four out of every five scleroderma patients are female, which he believes is connected to special features of the X chromosome. While there are two X chromosomes in every cell in a female body, every cell in a male body contains only one X chromosome plus a Y chromosome. In order to balance the gene products from the female X chromosomes to what is produced in male cells, one X chromosome is silenced in every female cell through a process called X-inactivation. Dr. Chang believes that this process of X-inactivation and the cellular machinery that carries it out might be involved in females’ increased susceptibility to scleroderma (as well as many other autoimmune diseases). In their quest to understand how X-inactivation might be involved, Dr. Chang’s group has discovered that many proteins that are autoantigens for autoimmune diseases work together with a special RNA molecule in silencing the extra X chromosome and they are investigating whether this association is involved in initiating autoimmunity. Dr. Chang’s group is also working to develop an animal model to further examine why autoimmunity might be skewed toward females.

Molecular Subsets, Integrative Genomics and Tissue Models of Scleroderma

Michael Whitfield, PhD
Dartmouth University School of Medicine

PROJECT OVERVIEW

Dr. Whitfield has been working for many years to develop a classifier via an artificial intelligence algorithm for scleroderma patients based on gene expression data. The goal is to predict how individual patients might respond to a given treatment. Because certain scleroderma treatments can be risky, or have serious side effects, it would be hugely advantageous for patients to understand upfront whether they are likely to respond to a potential treatment. For example, in the SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial, blood samples taken from patients prior to treatment were examined by Dr. Whitfield using his classifier. The classifier assigned each patient to one of three possible categories based on gene expression data obtained from their pretreatment sample. After determining which patients responded to transplantation and which didn’t, each of the three categories was analyzed to see if it was able to predict a response or not. The classifier was able to identify one category of patients likely to respond to transplantation while also identifying a category of patients that would likely NOT respond to transplantation. Dr. Whitfield hopes to be able to obtain additional samples from patients undergoing transplantation therapy to confirm these results. He is also working with other clinical trials to further explore the use of his classifier for predicting responsiveness to other treatments.

Measuring and Objectively Characterizing Patterns of Gastrointestinal Dysmotility in Scleroderma

Discovery of Novel Autoantigens in Scleroderma Patients with Gastrointestinal Dysmotility (in collaboration with Dr. Jay Pasricha, MD, Johns Hopkins University School of Medicine)

Dr. Zsuzsanna McMahan, MD
Johns Hopkins University School of Medicine

PROJECT OVERVIEW

Gastrointestinal (GI) disease is a common and often early complication for scleroderma patients. Its presentation varies from patient to patient, meaning that in individual patients, different parts of the digestive tract can be affected. The severity of GI dysfunction also varies. However, research on scleroderma GI disease has historically been lacking; thus, while subgroups of GI disease are thought to exist, too little data exists to definitively characterize different patterns of disease. Dr. McMahan is a Principal Investigator for two different SRF-funded GI projects aiming to generate additional data to help define subgroups of patients with different patterns of GI dysmotility. Subgrouping would help physicians better understand and treat the disease and even potentially to develop more tailored treatments. In one project, Dr. McMahan obtains direct measurements of transit time through the gut of scleroderma patients and will be able to determine overall variation in transit times as well as different patterns of transit. In a joint project with Dr. Jay Pasricha, Dr. McMahan is working to discover novel autoantigens in scleroderma patients with GI dysmotility and to determine if the autoantibodies associated with or can identify different subgroups of GI disease. By assessing patterns of gut transit, and correlating these patterns with known and novel autoantibodies, Dr. McMahan and her collaborators will enable researchers to better study GI disease in scleroderma and potentially to develop targeted treatments.

Assessment of Complement Cascade as a Novel Biomarker, Genetic Risk Factor, and Treatment Target for Scleroderma-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Dr. Ben Korman, MD
University of Rochester

PROJECT OVERVIEW

Scleroderma patients are frequently affected by vascular complications, which include Raynaud’s phenomenon, digital ulcers, cardiovascular disease, and pulmonary hypertension. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that affects the arteries of the lungs and the right side of the heart. Scleroderma-associated PAH (SSc-PAH) is a severe vascular manifestation of scleroderma that currently has poor outcomes, is under-diagnosed, has no established biomarkers, and responds poorly to standard pulmonary hypertension medication.

The complement cascade is an important part of the immune system that helps to clear microbes and damaged cells. Dr. Korman and his research group are studying the potential role of the complement cascade as a risk factor for SSc-PAH, a marker of disease onset and severity, and a potential treatment target for SSc-PAH. They have shown that circulating levels of complement factor D are altered in patients with scleroderma and particularly in patients with pulmonary hypertension. Further characterization of patients with SSc-PAH and mouse models of PAH have shown additional abnormalities in certain parts of the complement cascade. In evaluating the role of complement in SSc-PAH, Dr. Korman is using several different approaches. They are analyzing data from large-scale genetic studies (including the GRASP Project—see page 11) to evaluate variation in complement genes as a risk factor for SSc-PAH. They are also analyzing blood from SSc-PAH patients to evaluate the levels of various complement factors as possible SSc-PAH biomarkers. To assess whether blocking complement may be an effective therapeutic strategy for treating SSc-PAH, they will use genetic and pharmacologic approaches to treat mice with PAH and abnormalities in lung complement.
2019-2020 brought noteworthy achievements in the advancement of CONQUER (COlaborative, National Q(uality and Efficacy Registry), a first-of-its-kind, nationwide, longitudinal patient registry for scleroderma patients that was founded and is run by the SRF. As of mid-2020, CONQUER has enrolled over 300 unique patients. For each patient, clinical data and blood samples are periodically collected. This effort will yield a rich database and biorepository that can be used to track and understand the trajectory of scleroderma in different subsets of patients.

Additionally, clinicians, scientists and our pharmaceutical partners will use the underlying data to:

- determine which disease features are associated with or predict outcomes
- identify patients requiring early/aggressive intervention—as well as those to watch
- drive more personalized and effective therapy for patients.

As a critical, pre-competitive resource, we are proud to partner with our generous CONQUER corporate sponsors: Boehringer Ingelheim and Actelion. The SRF is grateful for their leadership and we look forward to including additional corporate partners in the coming year.

Previous epidemiological studies have indicated that African Americans are more likely to get scleroderma than Americans of European ancestry; they also tend to have an earlier age of onset of scleroderma and more severe disease. The Genome Research in African American Scleroderma Patients (GRASP) Project was established to enhance our understanding of the clinical manifestations of scleroderma in African American patients and to perform genomic analyses with the aim of identifying key factors contributing to the onset and severity of their disease.

The GRASP Project has obtained clinical data from a sufficiently large population of African American patients for researchers to better understand scleroderma in African American patients. Using the GRASP clinical data, researchers have confirmed the increased incidence, earlier age of onset and more severe disease in African American patients. They are also developing a better understanding of how scleroderma typically presents in African American patients, which will aid physicians in treating them.

Another goal of the GRASP Project is to generate a large set of genomic data, through DNA sequencing of scleroderma patient samples and control patient samples from other studies, that can be compared and used to determine whether specific scleroderma clinical manifestations correlate with specific DNA variants. Through these associations, researchers hope to learn about DNA variants that might affect scleroderma susceptibility, age of onset and disease severity. To achieve these goals, a large cohort of African American scleroderma patients has been gathered and clinical data as well as DNA samples have been collected from all enrolled patients.

The GRASP cohort currently consists of more than 1,300 extensively evaluated African American scleroderma patients enrolled from 23 participating US academic centers. This is the largest multi-center cohort of African American scleroderma patients ever studied. The SRF has been instrumental to the development of the GRASP Project since the very beginning.

The strong partnership with the GRASP leadership and the continued financial support provided by the SRF has enabled the participation of a large number of academic centers in the GRASP consortium. Moreover, the SRF has provided the perfect framework for GRASP, an environment that encourages brainstorming, formulation of ambitious research goals, and streamlined collaboration among leaders in the field of scleroderma research and clinical care.
Since its inception in 1986, Cool Comedy • Hot Cuisine (CCHC) has become our signature fundraising event, featuring some of the world’s greatest comedians and performing artists—all of whom donate their time and talents to support the SRF’s innovative research programs and help raise awareness about this rare autoimmune disease.

For more than 30 years, CCHC has been led by the indefatigable efforts of Board members Bob Saget and Susan Feniger. Attendees have included generous partners and supporters from the entertainment world and corporate industries, as well as patients, physicians and many other who have been directly or indirectly affected by scleroderma.

In this past period, three CCHC events, two in New York and one in Los Angeles, collectively raised an amazing $2.5 million to support the work of the SRF and our commitment to finding improved treatments and—a day—a cure for scleroderma!

**2018 New York Highlights**

**2019 Los Angeles Highlights**
COOL COMEDY HOT CUISINE

2019 New York Highlights

Deann Wright, Bob Saget and Luke Evnin
Melissa Brantina, Erin Marthia, and Lucille Milia
Susan Feniger and The Hot Cuisine team
Jim Gaffigan
Bob Saget and Gilbert Gottfried
John Oliver
Michael Che
Bob Saget and Susan Feniger
**Cure Crew**

A volunteer network where **YOU can make a difference!**

Cure Crew members make a real impact in the lives of people living with scleroderma and their loved ones – as well as honoring those who have died from complications caused by the disease. They know that lack of awareness causes delays in treatment or misdiagnosis, and fundraising research is the best hope of finding a cure. At the very heart of the program are people joined for a shared cause doing what they enjoy while helping to fund research and awareness campaigns.

In 2019 our Cure Crew members raised the bar by launching awareness-building campaigns, creating 2,607 Facebook fundraising pages and organizing innovative charity events. Their efforts inspire us and the scleroderma community to work together to find a cure!

**$50,000+**
- Kenzen Pharmaceuticals US, Inc.
- All Family Foundation
- Arthur Zinshbaum Foundation, Inc.
- Errans of Betty Z. Bender
- Budding Ingelheim
- Pharmaceutical Inc.
- Evenshied Sutherland
- Judy Erwin and Dr. Tony Erwin
- Dr. Luke Erwin
- Errans of Shahe M. Hann
- The Kac Family Foundation
- Andy and Vi Merin
- Brooks Manschtrum
- The Nancy P. and Richard K. Robbins Foundation
- Family Foundation
- Mark Scher
- Deane Wright

**$25,000 - $49,999**
- Errans of Maria D. Anagnostis
- The Anita May Rosenstein Foundation
- Corbus Pharmaceuticals, Inc.
- Cozen Family Foundation
- Tim and Mary Erwin
- Dr. Jeff Gevirtz
- Joseph Hufton
- Lamb Family Foundation
- Thomas Osborne and Jean Lowry
- John Mayer
- Bolker
- Adam and Tracie Sturm

**$10,000 - $24,999**
- John and Debra Aprenza
- BCS Private Wealth Management
- Joel and Bonnie Bergstein
- Blade Therapeutics, Inc.
- Kevin and Claudia Bright
- Sara and Buddy Campbell
- Andrea Oskarz and Jeff Chambers
- Maurer Collabor
- Dana Delany
- Vin and Erica Dr Rosa
- Dr. Sharon Duan
- Jon and Robin Dragoon
- Robert and Dana Emery
- Debbie and Greg Gnamore
- Bill and Marcy Helfand
- Mary Lou Housa
- Henry Jones
- Alen and Donna Kaniskofsky
- Ela Las and Dr. Eric Kau
- Errans of Mary Keith
- Kraft - Engel Management LLC
- Lear Family Foundation
- Norman and Sarah Livingston
- Kinkade Yoolac and George Lessing
- Rhonda Maas
- Scott Mara
- George and Suanna Mengsman
- MTS Health Partners, LP
- National Christian Foundation
- Brian Norkirk
- Sharon Anderson and Bob O’Neill
- Loren Otte
- Bob and Jula Pearlman
- Craig Smith and Laura Popo
- Mr. and Mrs. Steven J. Pryzcki
- Paul and Wendy Proudfoot
- Dr. William Prinzmetal
- Bob Saget
- Bob and Laura Smith
- Robert and Galloway Stave
- Eytan Sugarman
- Errans of Clinton Ternstrom
- Michael and Jovan Trapani
- Paul Wempner
- Sandy and Barbara Wisnuck
- Dr. Marc Tuchman and Vicky West
- Robert and Elaine Wexloff
- Errans of Mary Ann Wolff
- David Zagler
- Matthew Zino
- Caryn Zuckor

**Powering Our Research Until There’s a Cure**

Our ability to advance important science and facilitate the development of new treatments for all types of scleroderma is only possible with generous donor support. Acknowledgments listed here reflect contributions of $250 or more made to SRF between May 2018–December 2019.

- [image of page with text and images]
Thank you for your hard work and all you do!!

I was diagnosed with Scleroderma in 2006. I know that research is the heart of figuring out how to manage and defeat this disease. Thank you for your hard work and all you do!!

– Debra
with this disease. and others in the future who end up SRF is such a great way for me to help her day in and day out the toll it takes on her. Our Generous Donors

$250 - $999

Robert Hines
Melanie Hill
Dr. Wayne Herman and JoAnne Herman
Harris and Carrie Herman
Linda Heinberg
Michael Heilala
Joe and Jane Hegleman
Estate of Nellie T. Hay and Susan C. Hay
Crystal Hammer
Dennis Hadden and Marcia Reska-Hadden
Heidi Haas
Mr. Christopher P. Guthrie and Mrs. Lauren
Bonni Goldberg
Jill and Scott Glenn
Christian Vincent and Peri Gilpin
Jeffrey & Cynthia Gault Family Giving Fund
Letizia Gasparetti
Dave Galka
Mr. and Mrs. Eric Gabrielsen Borchardt Guthrie
(continued)

Laura Kuhlman
Ilene Kramer
Julia Kordestani
Angela Kooiker
Dr. Marki Knox
Don Knight
Casey Knight
Charles Klein
Keitha Kinne
Mr. and Mrs. Roger Kimber
Thomas W. Keilty
Kimberly Keilty
Robert Katz
John and Cynthia Pohlen
Yvonne Pinedo
PHE, Inc.
Julie Perez
Amy Duval and Lil Peloquin
Pella Rolscreen Foundation
Josh Peck
Debbi Pearlman
Cathy Paul
Brett Paul
Scott and Karen Patterson
Burne Paul
Cathy Paul
Doblin Pearlman
Josh Pack
Pella Rochevitz Foundation
Amy David and Lil’Hoggin
Julie Puzes
Kerr and Wendy Peterson
Frederick and Julia Pfennimilt"
In Memory

We express our deepest sympathy to the families and friends of the following people in whose memory gifts were made during our fiscal year.

Betty Gayle
Catalda Gasparetti
Layne Fudge
Charlie Freeny
Lori Dana Forman
Shane M. Flann
Rosina Flaccavento
Alyce Ferrari
Marilyn Feehan
Jim Fecko
Kay Etow
Ramona Esparza
Sally English
Rori Eisenberg
Cathy Eddy
Patricia Dziak
Emma S. Duvall
Vernon Dunn
Emma S. Downell
Patrick Drax
Carly Edly
Rien Eisenberg
Sally English
Ramona Esparraga
Kay Ewezen
Thelma Esswili
Guido J. Faun
Patrice Fauser
Jim Fetcher
Marylin Fuchian
Alyce Fioritti
Rostina Hackacaro
Shane M. Flann
Loi Dina Forman
Michael H. Fertman
Charlie Freeny
Layne Fudge
Marcelo Ghalibeth
Ann alta F Green
Carolina Guasperriti
Berry Gygle
Nancy Groetz
Judy A. Giangrande
Leslie S. Gilup
Pamela Goldberg
Francis Goldenstein
P. J. Gross
Lisa Rushin Goodman
Sharonia Graham
Hannah Grauer
Chadelle Monique Green
Glenda Bernice Gey
Marilyn Griswold
Sylvia Grosman
Christine Gaudiussi
Marguerite Gaudet
Dianne Hafley
Sarah Hagen
Carol Joan Hamilton
Jackie Harmon
Sarah Hazlehoff
Dorothy Heinlein
Ken Heller
Jennifer Henzl
Marilyn Helen Harmsand
Marilyn P. Hines
Kathryn Deid Hinsman
Hans K. Hock
Sally Hodges
Stace B. Hosper
Maryse Howard
Rabbi K. Hulman
Mary Neil Hutchinson
Shirle R. Jenkins
Galen Jerry
Noel L. Kasuma
Carla Kley
Mary T. Klein
Joyce Devana Kennedy
PriscillaCLI.
Yossi Kahn
Sandi J. Kinard
Ann Klein
Evelyn C. Klpec
Lauri Knedllik
Sharon Kostanian
Sandi Kuebler
Richard Krueger
Leon T. Lambeth
Beverly J. Larson
John LeBlanc
Daniel Loe
Yee Wai Leong
Beatrice Primus Lasfer
Ann LeBlanc
john LeBlanc
Beverly Leigh
Frederick Leone
Mrs. James Lillis
Rosalinda R. Lillis
Janee Lessman
Mary Lestern
Michael Lonetto
Donald Lowdach
Janice Lowry
Heidi Lohnes
Jeffrey H. Mace
Shingenobu Machida
Holm Mai
Jeanet Malnowski
Thomas I. Mamreichs
Joanne Marcus
Frank Martin
Gloria Marino
Sharon Martinez
Lusimma Mann
Andrea M. Matts
Andrea Matt
Gala Matt
Perry Mayo
Ruby C. McCaill
Jo-Ann Meaney
Toni Mikuleck
Theresa M. Mikuleck
Donald Miller
Paul Miller
Rita Millan
Lena Moccia
Rita Miller
Pam Miller
Teresa M. Valocchi
GD Uma
Marjorie B. Turner
Gwendolyn S. Turner
Carolyn Turner
Mary Turner
Garth Turner
Joseph P. Ziegler

"My mother died of systemic scleroderma after a progressively painful battle with the disease. She inspired and encouraged me to advocate for others less fortunate in life and health." – Christine
In Honor

Gifts made to the Scleroderma Research Foundation in honor of special people and milestones have a significant impact on our research. The following individuals were recognized during our fiscal year by family and friends who made a gift in their honor:

Adnah United Methodist Church
Amador United Methodist Church
Megan Arri
Kimberly Becker
Malisa Belgrave
Daniel Benamoz
Ronald Brez
Debbie Buckhoff
Charles Borg
BethAnneBoston
Robert L. Boyett
Patti Brown
Kevin Brunson
Laura Brogan
Umala A. Brown
Koren Bryant
Lorena G. Burton
Bemz Callaway
Amy Capell
Susan Cash
Maxine Charyka
Jean Collier
Mary Consomo
Stacie Cooper
Judith Croft
Gloria Crow
Catherine Cumbie
Monaco D’Ambrosio
Dominic G. Daye
Dana Dilany
Rebecca J. Dinolingo
Josee Dlouka
Triggy Donaldson
Glenda Durkan
Linda Dunbar
Lissa Edouard
Jeffry L. Eisenberg
Thomas Eisenberg
Laura Engel
Lake Erwin
Tami Eskel
Susan Fugger
Rebecca Fisher
Yervos Gambrel
Jeffrey Geertze
Catherine A. Gibbons
Randi Gimbarg
Brena Goldard
Vera Sue Goldrick
Daxine Graham
Brandi Green
Bruce Grossman
Margaret Gustafson
Sharon Hale
Nancy Halston
Barbara Jo Heelan
Barbara Hendricks
Evelyn Horwet Harris
Dai Hoppe
Olivia Howard
Winifred Huberty
Harry W. Humn
Robert S. Humn
Rachel Johnson
Kathryn Karson
Rena Kaufman
Saville Kellner
Margaret Kinastin
Katherine L. Kins
Margaret Kellind
Anna Kielb
LaRue Kiah
Diana Lambert
Mindy Langy
Fran Llewellyn
Lenora Lewis
Bill Linderson
Ted Logan
Laura Lopez
Don Manioncy
Susan Marcia
Katie McGraw
Lynn Morik
Holly Munkowitz
Lucille Miller
Tom Miller
Janice R. Moffett
Barbara Mexico
Josephine Parker
Jula Prinsensental
Diana Pringle
Shelley E. Raths
Blossom Ruck
Marina E. Ruff
Dawn Rucker
Robert M. Ruskirk
Sandra Rouse
Lauryl Rafoon
Bob Sager
Suzanne Sakris
Bobbi Salmon
Tammy Sauer
Cindy Schom
Vicky Schneider
Sophie Arna Scott
Jenni Seltle
Michele Shapiro
Christine A. Silver
Steven Smith
Beth A. Stewart
Barbara Sunsuri
Angela Swern
Anne Terrell Mattson
Wilma Jean Timms
Pat Vos Gosp
Elizabeth Vogel
Larie Wachter
June Waldman
Eve Warming
Beveryl Wiersburg
Marlene Wintzen
Nancy Whitney
Hodi Winkley
Maryclare Wilkinson
Devin Wright
Jack Zooknick
Barbara Zimmerman

“Someone I care about has just been diagnosed. Please find a cure!” – Roberto

Your Gifts At Work

Financial highlights

At the SRF, we take seriously our responsibility to the scleroderma community and we value donor trust above all else. To earn and maintain this trust, we work hard to maximize every dollar invested to advance research with the greatest potential to benefit patients and families. Research is at the center of all we do and it will continue to drive us until we ultimately eradicate this disease.

*Note: As we have changed our fiscal year; this report covers two periods - FY 2019 covering the 12 month period of May 1, 2018 through April 30, 2019 and a stub year period for the 6 remaining calendar months through December 2019. We will report henceforth on a calendar year basis.

FY May 2018 – April 2019

Total Annual Expenses: $3.8M

Total Expenses (6 Mos.): $1.3M

Stub Year May 2019 – December 2019*

Contributions – $2.9M
Bequests – $1.06M
Events – $1.5M
Investments – $200K

Contributions – $2.1M
Bequests – $115K
Events – $712K
Investments – $246K

Research – $2.5M
Education – $326K
Administration – $265K
Fundraising – $211K
Events – $457K

Research – $609K
Education – $1810K
Administration – $145K
Fundraising – $211K
Events – $457K

* Majority of research expenditures occurred in Q2 and are not reflected in stub year totals.

Total Annual Revenue: $5.7M

Total Revenue (6 Mos.): $3.2M

FINANCIALS